Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,144.2
-16.5 (-0.52%)

 

  • STI Straits Times Index
    3,144.2
    -16.5 (-0.52%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,566.2
    -7.9 (-0.50%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,566.7
    -219.5 (-0.82%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,941.6
    -12.8 (-0.43%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    22,625.4
    76.5 (0.34%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,237.4
    11.9 (0.19%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,080.6
    -8.2 (-0.39%)
    Index delayed 20 minutes
  • XAO XAO
    6,778.2
    -0.4 (-0.01%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 631.0M
  • Value: 754.4M
  • Rise: 119
  • Fall: 170
  • Unch: 542

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
SunMoonFood^0.067-0.002
Rex Intl0.096+0.001
Sembcorp Marine1.390+0.040
Golden Agri-Res0.210-
Mapletree Log Tr1.680+0.020
TEE Intl0.047+0.003
Capital World0.010-0.002
Singapore-eDev0.050-
SingTel3.240-0.020
AEM1.360+0.030

World Indices

World Indices
Name Last Change
Nasdaq 8,104.3 -58.7
HSI 26,566.7 -219.5
HSCEI 10,451.7 -75.2
Jakarta 6,234.4 +8.9
Nikkei 225 22,625.4 +76.5
SSE Comp 2,941.6 -12.8
Shanghai A 3,081.8 -13.4
Shanghai B 264.3 -1.3
PSE Comp 0.0
KOSPI 2,080.6 -8.2

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Suntar Eco-City^ SUNTAR ECO-CITY LIMITED
Quotes 10 Minutes Delayed. Updated at 23 Oct 2019 10:03
Last (SGD): 0.300 Change: - High: - Remarks: -
Change (%): - Low: -
Open - Yesterday's Close 0.300
Buy Price 0.300 Sell Price 0.450
Buy Volume ('000) 1.0 Sell Volume ('000) 5.0
Cumulative Volume ('000) - Cumulative Value -
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a -0.04265 Trailing EPS (SGD) e -0.04914 NAV (SGD) b 0.2641
PE a - Trailing PE f - Price / NAV b 1.1359
Dividend (SGD) d - Cash In Hand (SGD) g 0.0135 Issued & Paid-up Shares c 62,760,000
Dividend Yield (%) d - Price / Cash In Hand g 22.222 Treasury Shares h -
Beta - 75 Daysi -0.185 R-Squared - 75 Days(%)i 0.01 Market Cap (M) 18.828
Beta - 500 Daysi -0.434 R-Squared - 500 Days (%)i 0.26 Enterprise Value (M) 4.386
Piotroski F Score 4 Exchange Code BKZ Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 132.8924 6-Month VWAP 0.213 Free Float (%) -
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Manufacturing - Biotechnology
Category Classification China / Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 20 Aug 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Suntar Eco-City^ SGX 18.828 - - 1.1359 -
Industry Biotechnology SGX 1,987.662 7.340 9.734 0.6938 4.746
China SGX 603.576 22.045 43.101 0.7617 3.580
Medical & Biotechnology SGX 987.275 23.145 26.344 1.4217 1.828
Local Peer Lonza SGX 5,937.453 7.663 9.330 0.6935 4.766
Local Peer QT Vascular SGX 4.471 0.111 - 0.2632 -
Global Peer AMGEN INC NASDAQ 122,836.756 14.634 15.436 11.3801 2.706
Global Peer GILEAD SCIENCES INC NASDAQ 83,408.397 15.290 14.006 3.6880 3.504
Global Peer CSL ASX 113,805.144 42.418 42.418 15.2082 1.058
Global Peer AMGEN-T HKEx 599,701.000 9.116 9.612 7.1115 4.345
Global Peer CELGENE CORP NASDAQ 74,205.183 18.340 14.078 7.3829 -
Global Peer BIOGEN INC NASDAQ 51,990.076 11.734 9.820 4.0138 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 49,109.107 23.425 22.171 9.6863 -
Global Peer ILLUMINA INC NASDAQ 45,430.350 55.000 48.433 10.4871 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 33,112.267 13.546 16.002 3.3941 -
Global Peer AGILENT TECHNOLOGIES INC NYSE 23,114.165 73.146 21.562 4.8692 0.820
Other Global Peers ALEXION PHARMACEUTICAL INC (NASDAQ), SINO BIOPHARM (HKEx), INCYTE CORPORATION (NASDAQ), SEATTLE GENETICS INC (NASDAQ), WUXI BIO (HKEx), BIOMARIN PHARMACEUTICAL (NASDAQ), EXACT SCIENCES CORP (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), BEIGENE (HKEx), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), MODERNA INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), EXELIXIS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), 3SBIO (HKEx), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), GENSCRIPT BIO (HKEx), REPLIGEN CORP (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), FIBROGEN INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), NATERA INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), GENOMIC HEALTH INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), 10X GENOMICS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), XENCOR INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), UNIQURE N.V. (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), ALDER BIOPHARMACEUTICALS INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), REGENXBIO INC (NASDAQ), FRONTAGE (HKEx), OPKO HEALTH INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), VERACYTE INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), POLYNOVO LIMITED (ASX), DICERNA PHARMACEUTICALS INC. (NASDAQ), FATE THERAPEUTICS (NASDAQ), ALECTOR INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), VIELA BIO INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), EPIZYME INC (NASDAQ), VIVA BIOTECH (HKEx), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), HAOHAI BIOTEC (HKEx), LUMINEX CORP(DEL) (NASDAQ), AVITA MEDICAL LTD (ASX), CARA THERAPEUTICS INC (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), INTREXON CORP (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), KODIAK SCIENCES INC (NASDAQ), OMEROS CORP (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), CYTOKINETICS INC (NASDAQ), MESOBLAST LTD (ASX), NEXTCURE INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), CORTEXYME INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), ARVINAS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), MACROGENICS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), RETROPHIN INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), AVROBIO INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), ASCLETIS-B (HKEx), PROGENICS PHARMACEUTICALS INC (NASDAQ), CKLIFE SCIENCES (HKEx), MERIDIAN BIOSCIENCE INC COM (NASDAQ), IMMUNOGEN INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), ESSEX BIO-TECH (HKEx), SYNTHORX INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), DYNAVAX TECHNOLOGIES CORP (NASDAQ), DERMIRA INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), KADMON HLDGS INC (NYSE), PROQR THERAPEUTICS N V (NASDAQ), MERUS B V (NASDAQ), XBIOTECH INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), PERSONALIS INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), MEDICINOVA INC (NASDAQ), AGENUS INC (NASDAQ), NEXT SCIENCE LTD (ASX), PRECISION BIOSCIENCES INC (NASDAQ), LEE'S PHARM (HKEx), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), ARDELYX INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), RECRO PHARMA INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), GERON CORP (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), TELIX PHARMACEUTIC (ASX), PUMA BIOTECHNOLOGY INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), COMPUGEN (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), MANNKIND CORPORATION (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), RESTORBIO INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), GLYCOMIMETICS INC (NASDAQ), DPHARMA (Bursa), PFENEX INC (NYSE American), CHIASMA INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), KAMADA (NASDAQ), ATHERSYS INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), RESAPP HEALTH LIMITED (ASX), DYADIC INTERNATIONAL INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), AFFIMED N V (NASDAQ), CUE BIOPHARMA INC (NASDAQ), BICYCLE THERAPEUTICS LTD SPON ADS EACH REP 1 ORD SHS (NASDAQ), NANOVIRICIDES INC (NYSE American), BBI LIFE SCI (HKEx), ALDEYRA THERAPEUTICS (NASDAQ), XOMA CORP (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), ENZO BIOCHEM INC (NYSE), X4 PHARMACEUTICALS INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), IMV INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), NABRIVA THERAPEUTICS PLC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), UNI-BIO GROUP (HKEx), AXOVANT GENE THERAPIES LTD (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), SESEN BIO INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), JOUNCE THERAPEUTICS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), NANTKWEST INC (NASDAQ), PHYLOGICA LIMITED (ASX), HARVARD BIOSCIENCE INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), NOVAVAX INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), TREVENA INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), VERASTEM INC (NASDAQ), CHIMERIX INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), VACCINEX INC (NASDAQ), ARAVIVE INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), IMMUTEP LTD (ASX), CHAMPIONS ONCOLOGY INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 100 ORD SHS (NASDAQ), SYNLOGIC INC (NASDAQ), CEL-SCI CORP (NYSE American), GENOCEA BIOSCIENCES INC (NASDAQ), OTONOMY INC (NASDAQ), COHBAR INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), CURIS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), PORT (SET), EQUILLIUM INC (NASDAQ), INFLARX N V (NASDAQ), ORGENESIS INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), ORTHOCELL LIMITED (ASX), VERMILLION INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), INMUNE BIO INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), IBIO INC (NYSE American), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), ALPINE IMMUNE SCIENCES INC (NASDAQ), IMUGENE LIMITED (ASX), ITERUM THERAPEUTICS PLC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), CT ENTERPRISE (HKEx), ONCOSIL MEDICAL LIMITED (ASX), FORWARD PHARMA AS SPON ADS EACH REP 2 ORD SHS (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), IVERIC BIO INC (NASDAQ), EVOGENE LTD (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), BIONOMICS LTD (ASX), SURFACE ONCOLOGY INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), SAVARA INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), MEMPHASYS LTD (ASX), CELLDEX THERAPEUTICS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), REGENT PACIFIC (HKEx), BIOTRON (ASX), ACTINOGEN MEDICAL LTD (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), RHINOMED LIMITED (ASX), APTEVO THERAPEUTICS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), ZAFGEN INC (NASDAQ), BIOCARDIA INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), BIOSINO BIO-TEC (HKEx), EXTRAWELL PHAR (HKEx), SIERRA ONCOLOGY INC (NASDAQ), ORAGENICS INC (NYSE American), SENESTECH INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), INVEX THERAPEUTICS LTD NPV (ASX), AETERNA ZENTARIS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), OCUGEN INC (NASDAQ), PROTEOMICS INTL LABORATORIES LTD (ASX), GENETIC TECHNOLOGIES (ASX), SOLIGENIX INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), BIOCEPT INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), ISORAY INC (NYSE American), ACTINIUM PHARMACEUTICALS INC (NYSE American), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), IMMURON LIMITED (ASX), PATRYS LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), PRECIPIO INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), TOCAGEN INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), CELLECTAR BIOSCIENCES INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), REGENEUS LTD (ASX), ATYR PHARMA INC (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), ADALTA LTD (ASX), PULMATRIX INCORPORATED (NASDAQ), VAXART INC (NASDAQ), ANTEO DIAGNOSTICS LIMITED (ASX), BIONANO GENOMICS INC (NASDAQ), CELLMID LIMITED (ASX), HOLISTA COLLTECH LIMITED (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), ONCOLYTICS BIOTECH INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), BENITEC BIOPHARMA LTD (ASX), CONATUS PHARMACEUTICALS INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), TROVAGENE INC (NASDAQ), AUSTRALIAN PRIMARY HEMP LTD (ASX), BENITEC BIOPHARMA LTD SPON ADS EA REPR 20 ORD SHS (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), NOVABAY PHARMACEUTICALS INC (NYSE American), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), HAO WEN HLDGS (HKEx), ENDRA LIFE SCIENCES INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), MEGASUN (Bursa), XENETIC BIOSCIENCES INC (NASDAQ), BIOXYNE LIMITED (ASX), ADVAXIS INC (NASDAQ), LIVING CELL TECHNOLOGIES (ASX), ARCA BIOPHARMA INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), MEDIBIO LIMITED (ASX), TRILLIUM THERAPEUTICS INC (NASDAQ), MGRC (Bursa), ANATARA LIFESCIENCES LTD (ASX), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), AIM IMMUNOTECH INC (NYSE American), CYCLACEL PHARMA IN (NASDAQ), TBG DIAGNOSTICS LTD (ASX), CCP TECHNOLOGIES LTD (ASX), DIFFUSION PHARMACEUTICALS INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), PROTEON THERAPEUTICS INC (NASDAQ), OPGEN INC (NASDAQ), NOVITA HEALTHCARE LTD (ASX), NANOLLOSE LTD (ASX), AURIS MEDICAL HOLDING LTD (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), NEURALSTEM INC (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), SPHERIX INC (NASDAQ), BPH ENERGY LIMITED (ASX), AMPLIA THERAPEUTICS LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days ---
10 Days ---
20 Days -+0.005
+1.69 %
Medium Term Return 3 Months -+0.070
+30.43 %
6 Months -+0.180
+150.00 %
1 Year -+0.100
+50.00 %
Long Term Return 2 Years -+0.050
+20.00 %
3 Years -+0.155
+106.90 %
5 Years --0.100
-25.00 %
Annualised Return Annualised --
-5.59 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.100 - 0.300 Change From 1 Year Low +0.200 % Change From 1 Year Low (%) +200.00
Change From 1 Year High - % Change From 1 Year High (%) -
2 Years Range 0.100 - 0.300 Change From 2 Years Low +0.200 % Change From 2 Years Low (%) +200.00
Change From 2 Years High - % Change From 2 Years High (%) -
5 Years Range 0.100 - 0.800 Change From 5 Years Low +0.200 % Change From 5 Years Low (%) +200.00
Change From 5 Years High -0.500 % Change From 5 Years High (%) -62.50
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

The Company was incorporated in Singapore on 22 September 2006 as a private limited company under the name Reyphon Agriceutical Pte Ltd. The Company was renamed to Reyphon Agriceutical Limited on 13 July 2007.
The Group's principal products are gibberellic acids, a plant growth regulator, and validamycin, a plant antibiotic. The Group also possess the know-how to produce fermentation-based pesticides. Its main product, gibberellic acids, is used in China mainly in the cultivation of hybrid rice, cotton, fruits and vegetables. Through active R&D, its objective is to widen the applications of gibberellic acids to cultivation of other plants such as tea plants, peanuts and soybean and lower its production costs and offer customers greater value with our gibberellic acids products.The Group manufactured, agriceutical products may be broadly classified into the following categories:-
(a) plant growth regulators;
(b) pesticides which include plant antibiotics, insecticide and weedicides; and
(c) fertilisers.

Its production facilities are located in Southern Industrial Development Zone of Xin?gan County, Jiangxi Province of China on a land area of approximately 65,002 sq m. Its products are sold throughout China such as Zhejiang, Fujian, Guangdong, Guangxi, Yunnan, Jiangsu, Shangdong, Hebei, Xinjiang, Anhui, Hainan, Hunan, Sichuan and Hubei. The Group also exports its products to countries such as United States, India, Turkey, Belgium, Canada, Germany, Malaysia, Pakistan, Spain, United Kingdom and Vietnam.

Change of Name:
Reyphon Agriceutical Limited to Suntar Eco-City Limited. Trading under the new name wef 14 June 2012.

Current core business of the Group has hereby expanded to include the eco-tourism real estate development and management business.

IPO Performance

Listing Date 01 Aug 2007 Full Subscription Rate (x) 13.55
No of Placement Shares (M) 76.60 No of Public Offer Shares (M) 2.00 Public Offer Subscription Rate (x) 494.05
IPO Price (SGD) a 1.950 First Day Close (SGD) a 3.050 First Week Close (SGD) a 2.500
Current vs IPO Price (%) -84.62 First Day Gain (%) +56.41 First Week Gain (%) +28.21
Notes:
  1. Adjusted for the following: Share Consolidation 1 for 5 on 19/11/2015

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2018 Dec 2018 Part 1(3.17 MB)
Annual Report 2017 Dec 2017 Part 1(4.01 MB)
Annual Report 2016 Dec 2016 Part 1(1.06 MB)
Annual Report 2015 Dec 2015 Part 1(1.97 MB)
Annual Report 2014 Dec 2014 Part 1(1.50 MB)
Annual Report 2013 Dec 2013 Part 1(0.95 MB)
Annual Report 2012 Dec 2012 Part 1(0.51 MB)
Annual Report 2011 Dec 2011 Part 1(0.64 MB)
Annual Report 2010 Dec 2010 Part 1(0.85 MB)
Annual Report 2009 Dec 2009 Part 1(0.98 MB)
Annual Report 2008 Dec 2008 Part 1(1.53 MB)
Annual Report 2007 Dec 2007 Part 1(1.61 MB)
IPO Prospectus
IPO Prospectus 2007 Jul 2007 Part 1(3.22 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
22 Oct 2019 0.300 0.300 0.300 0.300 - -
21 Oct 2019 0.300 0.300 0.300 0.300 - -
18 Oct 2019 0.300 0.300 0.300 0.300 - -
17 Oct 2019 0.300 0.300 0.300 0.300 - -
16 Oct 2019 0.300 0.300 0.300 0.300 - -
15 Oct 2019 0.300 0.300 0.300 0.300 - -
14 Oct 2019 0.300 0.300 0.300 0.300 - -
11 Oct 2019 0.300 0.300 0.300 0.300 - -
10 Oct 2019 0.300 0.300 0.300 0.300 - -
09 Oct 2019 0.300 0.300 0.300 0.300 - -
08 Oct 2019 0.300 0.300 0.300 0.300 2,000 0.3000
07 Oct 2019 0.300 0.300 0.300 0.300 - -
04 Oct 2019 0.300 0.300 0.300 0.300 - -
03 Oct 2019 0.300 0.300 0.300 0.300 - -
02 Oct 2019 0.300 0.300 0.300 0.300 - -
01 Oct 2019 0.300 0.300 0.300 0.300 - -
30 Sep 2019 0.300 0.300 0.300 0.300 - -
27 Sep 2019 0.300 0.300 0.300 0.300 7,000 0.3000
26 Sep 2019 0.295 0.295 0.295 0.295 - -
25 Sep 2019 0.295 0.295 0.295 0.295 10,000 0.2950
24 Sep 2019 0.295 0.295 0.295 0.295 - -
23 Sep 2019 0.295 0.295 0.295 0.295 - -
Summary
Current 2 Weeks
(09 Oct 2019 to 22 Oct 2019)
0.300 0.300 0.300 0.300 - -
Previous 2 Weeks
(25 Sep 2019 to 08 Oct 2019)
0.295 0.300 0.295 0.300 19,000 -
4 Weeks from
(28 Aug 2019 to 24 Sep 2019)
0.290 0.300 0.290 0.295 12,000 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.